Licensing Opportunities available from Warwick Innovations
 |
 |
 |
 |
 |
 |
| Biology | Chemistry | Computing | Engineering | Medicine | Physics |
These pages contain details of the technologies currently available to licence from Warwick Innovations.
If you would like more details of any of these technologies, please contact the relevant Business Development
Manager.
New technologies are added regularly, so do please register your interest and we will send through details of
opportunities as they are published. You can also use the RSS feed on the Licensing Opportunities page to
keep up to date.
Rapid diagnostic test for SARS-CoV-2
Coronavirus diagnostics currently require centralised facilities and collection/distribution of swabs and results are ‘next day’. A new diagnostic tool being developed by the University of Warwick and its partner Iceni Diagnostics may allow on-the-spot detection of Coronavirus infection, without facilities using a simple disposable device.
More details: Rapid diagnostic test for SARS-CoV-2
Contact: Dr James Lapworth, Warwick Innovations email: j.lapworth@warwick.ac.uk
IVF pre-implantation screening method
A team at the University of Warwick has developed a new screening test that potentially provides an accurate and noninvasive method for assessing embryos during IVF treatment, prior to implantation.
More details: IVF pre-implantation screening method
Contact: Dr Suzanna Wood, Business Development Manager, Warwick Ventures. Tel: 
+44 (0)24 765 75490; email: s.k.wood@warwick.ac.uk
Increased Epigenetic Variation in Plants
A team at the University of Warwick has developed technology to increase the epigenetic variety of plants without the usual undesired side effects. The novel strategy allows a much greater range of epigenetic and phenotypic differences to be introduced than was previously possible.
More details: Increased epigenetic variation in plants
Contact: Dr Suzanna Wood, Business Development Manager, Warwick Ventures. Tel: +44 (0)24 765 75490; email: s.k.wood@warwick.ac.uk
A novel target and therapeutic leads for the treatment of bovine and human RSV
Warwick Ventures has available for licence a patent application covering an entirely novel conserved host cell protein target for the treatment of bovine and human RSV. Promising proof-of-concept studies have demonstrated significant anti-viral activity with a number of chemical lead compounds which are suitable for entry into a drug discovery program.
More details: A novel target and therapeutic leads for the treatment of bovine and human RSV
Contact: Andrew Lee, Business Development Manager, Warwick Ventures. Tel: +44 (0)24 765 75745; email: L.Lane@warwick.ac.uk